Nama : Rosmida Valentina Simanullang

Nim : 4203220014
Penyimpanan dan HPC berkinerja tinggi persyaratan komputasi tidak signifikan tetapi dapat
dicapai melalui beberapa teknologi dan vendor yang telah terbukti.
Jenis layanan sekuensing apa yang akan Anda tawarkan?
Kami percaya tiga syarat utama bagi para peneliti saat ini adalah urutan pertama, berkualitas
tinggi dengan perputaran tepat waktu dan harga yang kompetitif, kedua, interpretasi data urutan mentah
dan ketiga, infrastruktur komputasi, mengingat ukuran besar data yang dihasilkan oleh setiap urutan.
NYGC menawarkan paket genomik terintegrasi yang menggabungkan ketiga bidang tersebut. Setiap
proyek dimulai dengan proses konsultasi awal, di mana pelanggan berkolaborasi dengan personil
sekuensing dan bioinformatika untuk menyesuaikan layanan yang diberikan berdasarkan proyek yang
bersangkutan. Saat ini, kami menawarkan seluruh genom, seluruh exome dan sekuensing mRNA. Selama
tahun depan, kami juga akan mulai menawarkan aplikasi yang ditargetkan khusus dan sekuensing RNA
kecil, metilasi, imunomoditation kromatin dan lain-lain, serta sekuensing genom non-manusia.
Bagaimana dengan aplikasi sekuensing klinis?
Saat ini, semua layanan NYGC adalah untuk aplikasi penelitian. Tetapi kami berkomitmen untuk
memajukan janji obat genom dan meningkatkan ketersediaan sekuensing untuk penggunaan klinis. New
York memiliki populasi pasien yang paling beragam di dunia menjadikannya tempat yang ideal untuk
memasukkan populasi yang kurang terlayani dalam uji klinis. Setiap tahun, lembaga medis akademik
kami yang berpartisipasi memiliki 1,2 juta penerimaan rumah sakit, 3,7 juta kunjungan ruang gawat
darurat dan 17 juta kunjungan rawat jalan. Kami berharap bahwa aplikasi genomik klinis akan tumbuh
dari waktu ke waktu, terutama mengingat inisiatif yang sedang berlangsung untuk membuka laboratorium
bersertifikat Clinical Laboratory Improvement Amendments (CLIA) di dalam fasilitas NYGC. Kami
mengantisipasi memiliki fasilitas yang disetujui CLIA dan berjalan pada akhir tahun depan, yang
kemungkinan akan menjadi inti utama dari operasi kami. Kami telah merancang fasilitas kami sehingga
ukuran dan konfigurasi laboratorium dapat dengan mudah diubah, dan kami telah secara khusus
membangun dalam kapasitas untuk memperluas laboratorium CLIA saat operasinya ditingkatkan. NYGC
is collaborating with institutional members NewYork-Presbyterian Hospital and North Shore-LIJ [Long
Island Jewish] Health System and experts in its participating institutions to develop this effort. In addition
to the regulatory and logistical challenges that will be met to open this facility,
NYGC will be working with its members to develop innovative genetics counseling, data sharing and
security approaches that ensure proper patient consent and privacy protection and address other ethical
issues.
How do you plan to collect and store samples for sequencing?
We are developing an integrated solution that will ultimately cover all processes spanning bench to
bedside, beginning with tissue banking and storage and culminating with new diagnostics, therapeutics
and therapies. To that end, NYGC is actively looking to partner with a biobanking company to provide
the tissue banking capability for our internal research as well as that of our founding institutions. Through
our scientific working groups and ongoing discussions with New York State healthcare and scientific
policy makers, we will facilitate dialog around patient consent and other ethical issues as technology
continues
to advance.What about data sharing between the center and the institutions?
The plan is to work closely with our founding institutions and other partners to identify synergies. Over
the coming months, we will initiate working groups to establish plans for how the respective clinical labs
will work together and create a model for sharing of clinical data. At present, this is largely uncharted
territory, especially given New York’s stringent regulatory environment. NYGC is committed to being an
innovator and leader in this space, and one of our goals involves the dedicated pursuit of change in that
realm. We hope to serve as a positive influence, through discussion and cooperation with New York State
healthcare and scientific policy makers, for reducing the regulatory barriers to pursuing this important
research and ultimately advancing clinical care.
What about training programs?
NYGC is committed to serving as a fulcrum for genomics training, leveraging the expertise of its
founding institutions and developing its own programs and courses through a dedicated training center.
We will carry out courses, lab rotations, internship programs, conferences and lecture series. For example,
several genomics courses are planned for next year where we work with scientists from founding
institutions. In addition, we are currently kicking off a collaboration with Cold Spring Harbor Laboratory
to co-sponsor a joint medical genomics conference in Manhattan in 2014. Additional training can be
provided online as part of NYGC’s growing web-based presence, a strategy designed to create true
thought leadership and to facilitate and lead the global discussion around sequencing and genomics.
What do you see as commercial
opportunities for the center?
NYGC will offer its integrated genomics solutions to pharmaceutical and diagnostic companies, as well
as co-develop its own unique solutions and processes. These relationships
will range from traditional fee-for-service
arrangements to corporate memberships or
more extensive research collaborations. We
will also provide incubators and investment
funds to spur the creation of spinouts and successful ventures. Subsidized space, equipment
and managerial support (including entrepreneurial education) will be made available to
facilitate technology commercialization. Our
innovation center will be our first such incubator-type space.